Todos Medical Ltd. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by COMMISSIONG GERALD, was filed 29 Mar 2023.
Todos Medical Ltd.: what insiders have been doing
This page follows insider dealings at Todos Medical Ltd. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Nothing new has been filed by managers of Todos Medical Ltd. in twelve months, the latest record being from 29 March 2023.
Our records for Todos Medical Ltd. go back to 2021, with 6 purchases and 8 sales on the open market in total.
Elsewhere in the same sector, our signals recently picked up insider purchases at Xenon Pharmaceuticals Inc. and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Since the insiders bought
- -88.9%Entry US$0.00 · Close at T+365 US$0.00
- -70.2%Entry US$0.05 · Close at T+365 US$0.01
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2021FY ended December 2021 · cache
- 5,000,000 shares@ US$0.0009100.0% of flowOrdinary SharesSEC:0001493152-23-009409:0Canonical exit: 26 Jun 2023 (T+90)
- 1,000,000 shares@ US$0.03248.3% of flowOrdinary SharesSEC:0001493152-22-023920:0Canonical exit: 22 Nov 2022 (T+90)
- 1,051,480 shares@ US$0.03445.4% of flowOrdinary SharesSEC:0001493152-21-016433:0Canonical exit: 28 Sept 2021 (T+90)
- 150,000 shares@ US$0.05380.5% of flowCommon StockSEC:0001493152-21-008825:0
- 100,000 shares@ US$0.05560.3% of flowCommon StockSEC:0001493152-21-008825:1
- 100,000 shares@ US$0.05650.3% of flowCommon StockSEC:0001493152-21-008825:2
- 98,300 shares@ US$0.0560.3% of flowCommon StockSEC:0001493152-21-008825:3
- 1,149,425 shares@ US$0.0775.0% of flowCommon StockSEC:0001493152-21-008825:4
- 1,724,139 shares@ US$0.0777.5% of flowCommon StockSEC:0001493152-21-008825:5
- 18,608,113 shares@ US$0.07785.3% of flowCommon StockSEC:0001493152-21-008823:2Canonical exit: 5 Oct 2020 (T+90)
- 100,000 shares@ US$0.0530.3% of flowCommon StockSEC:0001493152-21-008823:3
- 150,000 shares@ US$0.0520.4% of flowCommon StockSEC:0001493152-21-008823:4
- 17,091,096 shares@ US$0.059Common StockSEC:0001493152-21-008823:0Canonical exit: 20 Apr 2020 (T+90)
- 13,008,976 shares@ US$0.077Common StockSEC:0001493152-21-008823:1Canonical exit: 30 Jun 2020 (T+90)
14 of 14 declarations
About Todos Medical Ltd.
Todos Medical Ltd. is a U.S.-reporting healthcare company followed by investors through SEC disclosures, including Form 4 insider transaction filings. In a NYSE/NASDAQ framing, it should be viewed not as a large listed healthcare platform but as a small-cap, highly speculative diagnostics and life-sciences name with limited scale and a strong reliance on financing, partnerships, and commercialization execution. The company describes itself as an in vitro diagnostics business focused on developing novel blood tests for early cancer detection and neurodegenerative disorders such as Alzheimer’s disease, alongside the distribution of COVID-19 screening-related solutions. Its portfolio includes the TBIA cancer-screening platform, the Videssa Breast blood test, the LymPro Alzheimer’s blood test, lab-solution offerings, and 3CL protease-inhibitor related assets, including Tollovid and Tollovir.
Founded in Rehovot, Israel, Todos Medical says it has offices in New York City, while its website also lists a Tel Aviv address and a U.S. office in New York. That dual footprint reflects an international setup, but also a business model that has depended heavily on external capital and collaboration to move programs forward. The company’s recent history has included partnerships and asset development around Provista Diagnostics, a CLIA/CAP-certified lab in Georgia, and efforts to commercialize blood-based diagnostics and immune-support products. Its public communications emphasize blood-based screening technologies and a broader diagnostic pipeline aimed at cancer and Alzheimer’s, but the company remains an emerging player rather than a category leader.
Read moreShow less
From a competitive standpoint, Todos operates in a crowded and demanding market where diagnostic companies must validate clinical utility, navigate regulatory requirements, and convert R&D into repeatable revenue. The company’s claimed differentiation lies in its blood-based approaches and proprietary technologies, yet its commercial footing remains limited and its risk profile elevated. A key recent event was the December 2023 announcement of insolvency proceedings in Israel, which is highly material for fundamental investors and underscores the company’s financial stress and going-concern risk. That development should be treated as a central part of any SEO-ready investor description. For French-speaking investors, Todos Medical Ltd. is best characterized as a U.S.-linked healthcare micro-cap with scientific optionality, international operations, and a very high risk/reward profile rather than a mature NYSE/NASDAQ healthcare franchise.
